Title: Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in
nonalcoholic steatohepatitis
Version: 1 Date: 28 Oct 2022
Reviewer's report:
Dear authors
Thank you for your efforts.
Revising your manuscript ,it needs the following clarifications:
Could this sCD63 differentiate simple steatosis from NASH?
Please define clearly at which time point the levels of sCD163 are described through out your
manuscript  whether at base line or follow up and also in the title of table 1.
Lines 65-66:  What do you mean?
Lines 88 : Please add the details of liver core tissue obtained  ( length, number of portal tracts, .....)
Lines 124-127 : the sensitivity and specificity for fibrosis and steatosis are low to be
defined as "suitable".
Line 131-137: Please define "progression, stationary and improvement" of fibrosis and steatosis
in terms of  score changes .
Lines: 145-146 "13 had HCC and 15 died " is it all cause mortality ? cause of death ?
The discussion is long actually lines 159-171 is a new introduction.
Please add the p value for Figure 1c ,1d.
Title: Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in
nonalcoholic steatohepatitis
Version: 1 Date: 28 Oct 2022
Reviewer's report:
Dear authors
Thank you for your efforts.
Revising your manuscript ,it needs the following clarifications:
Could this sCD63 differentiate simple steatosis from NASH?
Please define clearly at which time point the levels of sCD163 are described through out your
manuscript  whether at base line or follow up and also in the title of table 1.
Lines 65-66:  What do you mean?
Lines 88 : Please add the details of liver core tissue obtained  ( length, number of portal tracts, .....)
Lines 124-127 : the sensitivity and specificity for fibrosis and steatosis are low to be
defined as "suitable".
Line 131-137: Please define "progression, stationary and improvement" of fibrosis and steatosis
in terms of  score changes .
Lines: 145-146 "13 had HCC and 15 died " is it all cause mortality ? cause of death ?
The discussion is long actually lines 159-171 is a new introduction.
Please add the p value for Figure 1c ,1d.
Please review this paper.
user
Title: Soluble CD163 is a predictor of fibrosis and hepatocellular carcinoma development in
nonalcoholic steatohepatitis
Version: 1 Date: 28 Oct 2022
Reviewer's report:
Dear authors
Thank you for your efforts.
Revising your manuscript ,it needs the following clarifications:
Could this sCD63 differentiate simple steatosis from NASH?
Please define clearly at which time point the levels of sCD163 are described through out your
manuscript  whether at base line or follow up and also in the title of table 1.
Lines 65-66:  What do you mean?
Lines 88 : Please add the details of liver core tissue obtained  ( length, number of portal tracts, .....)
Lines 124-127 : the sensitivity and specificity for fibrosis and steatosis are low to be
defined as "suitable".
Line 131-137: Please define "progression, stationary and improvement" of fibrosis and steatosis
in terms of  score changes .
Lines: 145-146 "13 had HCC and 15 died " is it all cause mortality ? cause of death ?
The discussion is long actually lines 159-171 is a new introduction.
Please add the p value for Figure 1c ,1d.
assistant